Anticancer Section / Original Paper
Fanelli F. · Hohaus S. ·
Cantonetti M. · Cimino G. · Pennese E. · Battistini R. ·
Galli E. · Cerretti R. · Proia A. · Fatone F. · Provenzano I. ·
Abruzzese E. · Finolezzi E. · Pulsoni A. ·
Rigacci L.
Log in to MyKarger to check if you already have access to this content.
Buy
FullText & PDF
Unlimited re-access via MyKarger
Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *
Select
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Learn more
Access via DeepDyve
Unlimited fulltext viewing of this article
Organize, annotate And mark up articles
Printing And downloading restrictions apply
Select
Subscribe
Access to all articles of the subscribed year(s) guaranteed for 5 years
Unlimited re-access via Subscriber Login or MyKarger
Unrestricted printing, no saving restrictions for personal use
read more
Subcription rates
Select
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
Abstract
Background: Allogeneic transplant is an effective salvage therapy in patients with Hodgkin lymphoma (HL) relapsed or refractory to previous treatments. In recent years, immunotherapies (conjugated antibody and checkpoint inhibitors) showed interesting results and were used as bridge therapies to allotransplant.
Aim: The aim of this retrospective study in Lazio Region was to evaluate the impact of these new therapies on outcome after allogeneic hematopoietic stem cell transplantation (allo-SCT) in comparison with standard chemotherapies used in the past.
Methods: We selected all consecutive patients with diagnosis of HL transplanted in four Hematology Transplant Unit and we collected data obtained from patients’ records concerning all the treatments before allo-SCT.
Results: A total of 56 patients were enrolled into this study. All patients underwent allo-SCT for relapsed or refractory HL. Seventeen patients (30%) received chemotherapy prior to allo-SCT (group B), they were treated between 2008 and 2015, and 39 patients (70%) received BV or CPI or both before allo-SCT as bridge to transplant (group A), they were treated between 2012 and 2020. Twenty-five patients were treated with BV alone, 2 with CPI alone and 12 first with BV and then with CPI. No patient received concomitant BV and CPI. At five years from allo-SCT, OS was 59% and PFS was 65%. No statistical differences in OS or PFS were observed between patients of group A and B. Relapse was significantly associated with a lower survival. The only factor associated with a reduced risk of relapse was development of any grade acute GVHD (p>0.02).
Conclusions: This regional real-world experience shows the changes that have taken place in the last 10 years in R/R HL using new drugs to render a patient eligible to allo-SCT. This strategy appears to guarantee an impressive disease control with an increased risk of complications, as aGVHD, that appear to nullify this advantage at least in part.
S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
留言 (0)